Compare Sana Biotechnology Inc (SANA) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $1.03B), while YieldMax TSLA Option Income Strategy ETF trades at $22.47. Which is the better fit depends on your goals.
| SANA | TSLY | |
|---|---|---|
Market Cap | $1.03B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $5.92 | $48.25 |
52-Week Low | $2.68 | $20.49 |
Enterprise Value | $946.04M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
TSLY trades at $22.79, up 3.17% with a bullish technical signal despite bearish moving averages. The ETF maintains consistent weekly dividend distributions ranging from $0.18 to $0.28, though recent analysis highlights concerns about underperformance relative to Tesla's underlying stock. Technical indicators show neutral oscillators with RSI at 59.70, while support and resistance cluster around $22-$24 levels.
The outlook remains mixed with high yield appeal offset by structural limitations in capturing Tesla's upside. Key risks include volatility dependency and capped growth potential. Investors face the trade-off between income generation and capital appreciation in this option-income strategy ETF.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
